HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
3.330
-0.075 (-2.20%)
Oct 17, 2025, 4:00 PM EDT - Market closed
HeartSciences Revenue
HeartSciences had revenue of $1.90K in the quarter ending July 31, 2025. This brings the company's revenue in the last twelve months to $6.25K, down -66.40% year-over-year. In the fiscal year ending April 30, 2025, HeartSciences had annual revenue of $4.35K, down -76.61%.
Revenue (ttm)
$6.25K
Revenue Growth
-66.40%
P/S Ratio
1,615.86
Revenue / Employee
$417
Employees
15
Market Cap
10.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.35K | -14.25K | -76.61% |
| Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
| Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
| Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
| Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HSCS News
- 5 weeks ago - HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results - GlobeNewsWire
- 2 months ago - HeartSciences Announces Conference Participation and Investor Webinar - GlobeNewsWire
- 3 months ago - HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results - GlobeNewsWire
- 4 months ago - HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis - GlobeNewsWire
- 4 months ago - Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value - GlobeNewsWire
- 5 months ago - HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone - GlobeNewsWire
- 5 months ago - HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025 - GlobeNewsWire
- 5 months ago - HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson - GlobeNewsWire